FDA
-
-
-
-
-
-
-
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
-
-
-
-
-
-
-
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
-
-
-
-
-
-
-
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
-
-
-
-
-
-
-
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
-
-
330,515 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

